[1] Arber D A,Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016,127(20):2391-2405.
[2] Adès L, Chevret S, Raffoux E, et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients[J]. Am J Hematol, 2013,88(7):556-559.
[3] Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initia ltherapy for patients with acutepromye locyticleukemia[J]. Haematologica,2012,97(2):227-234.
[4] Sanz M A, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy:long-term outcome of the LPA 99 multicenter study by the PETHEMA Group[J]. Blood,2008,112(8):3130-3134.
[5] Adès L, Guerci A, Raffoux E, et al. European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy:the European APL Group experience[J]. Blood, 2010,115(9):1690-1696.
[6] Eghtedar A, Rodriguez I, Kantarjian H, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with alltrans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide[J]. Leuk Lymphoma,2015,56(5):1342-1345.
[7] Lobe I, Rigal-Huguet F, Vekhoff A, et al. Myelodysplastic syndrome after acute promyelocytic leukemia:the European APL group experience[J]. Leukemia,2003,17(8), 1600-1604.
[8] Latagliata R, Petti M C, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia:an emerging problem[J]. Blood,2002, 99(3):822-824.
[9] Montesinos P, González J D, González J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy[J]. J Clin Oncol,2010,28(24):3872-3879.
[10] 李建勇,陆化,潘金兰,等.继发于急性早幼粒细胞白血病的治疗相关性急性单核细胞白血病一例[J]. 中华血液学杂志,2003,24(12):669.
[11] 郑正津,张浪辉,王少元,等.急性早幼粒细胞白血病缓解后继发白血病三例并文献复习[J].中华血液学杂志, 2012,33(8):672-673.
[12] Imagawa J, Harada Y, Shimomura T, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia[J]. Blood, 2010, 116(26):6018-6022.
[13] Eghtedar A, Rodriguez I, Kantarjian H,et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide[J]. Leuk Lymphoma,2015,56(5):1342-1345.
[14] Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia[J]. N Engl J Med, 2013,369(2):111-121.
[15] Cho H W, Choi Y B, Yi E S,et al. Therapy-related myeloid neoplasms in children and adolescents[J]. Blood Res, 2016,51(4):242-248.
[16] Montesinos P, González J D, González J, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy[J]. J Clin Oncol,2010,28(24):3872-3879.
[17] Litzow M R, Tarima S, Pérez W S, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia[J]. Blood, 2010,115(9):1850-1857. |
